MX2020004140A - Composiciones y metodos para la eliminacion de celulas cd117+. - Google Patents
Composiciones y metodos para la eliminacion de celulas cd117+.Info
- Publication number
- MX2020004140A MX2020004140A MX2020004140A MX2020004140A MX2020004140A MX 2020004140 A MX2020004140 A MX 2020004140A MX 2020004140 A MX2020004140 A MX 2020004140A MX 2020004140 A MX2020004140 A MX 2020004140A MX 2020004140 A MX2020004140 A MX 2020004140A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- compositions
- hematopoietic
- population
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención proporciona composiciones y métodos útiles para la eliminación de células CD117+ y para el tratamiento de diversas enfermedades hematopoyéticas, trastornos metabólicos, cánceres, por ejemplo, leucemia mieloide aguda (AML) y enfermedades autoinmunitarias, entre otros. En el presente documento se describen anticuerpos, fragmentos de unión a antígeno y conjugados de los mismos que pueden aplicarse para efectuar el tratamiento de estas afecciones, por ejemplo, eliminando una población de células CD117+ en un paciente, tal como un ser humano. Las composiciones y métodos descritos en el presente documento pueden usarse para tratar directamente un trastorno, por ejemplo, eliminando una población de células cancerosas o células autoinmunitarias CD117+. Las composiciones y métodos descritos en el presente documento también pueden usarse para preparar a un paciente para la terapia de trasplante de células hematopoyéticas y para mejorar el injerto de trasplantes de células madre hematopoyéticas eliminando de manera selectiva las células madre hematopoyéticas endógenas antes del procedimiento de trasplante.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762576572P | 2017-10-24 | 2017-10-24 | |
US201762596569P | 2017-12-08 | 2017-12-08 | |
US201862632967P | 2018-02-20 | 2018-02-20 | |
US201862638053P | 2018-03-02 | 2018-03-02 | |
PCT/US2018/057180 WO2019084064A2 (en) | 2017-10-24 | 2018-10-23 | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004140A true MX2020004140A (es) | 2020-08-13 |
Family
ID=66247007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004140A MX2020004140A (es) | 2017-10-24 | 2018-10-23 | Composiciones y metodos para la eliminacion de celulas cd117+. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10899843B2 (es) |
EP (1) | EP3700568A4 (es) |
JP (2) | JP7280254B2 (es) |
KR (1) | KR20200069364A (es) |
CN (1) | CN111372608B (es) |
AU (1) | AU2018355244A1 (es) |
BR (1) | BR112020008228A2 (es) |
CA (1) | CA3079897A1 (es) |
CO (1) | CO2020004906A2 (es) |
IL (1) | IL274154A (es) |
MX (1) | MX2020004140A (es) |
SG (1) | SG11202003280SA (es) |
WO (1) | WO2019084064A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019084064A2 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
US20200376135A1 (en) * | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
JP2022530443A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | 抗cd117抗体薬物複合体およびその使用 |
JP2022530442A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | アントラサイクリン抗体薬物複合体およびその使用 |
CN113993550A (zh) * | 2019-04-24 | 2022-01-28 | 美真达治疗公司 | 用于基因疗法的调理方法 |
AU2020261405A1 (en) * | 2019-04-24 | 2021-12-23 | Crispr Therapeutics Ag | Anti-CD117 antibodies and uses thereof |
CA3140180A1 (en) * | 2019-06-04 | 2020-12-10 | Geoffrey O. GILLARD | Methods and compositions for treating autoimmune diseases |
JP2022536094A (ja) * | 2019-06-05 | 2022-08-12 | マジェンタ セラピューティクス インコーポレイテッド | T細胞を除去する治療法 |
JP2023520636A (ja) * | 2020-03-16 | 2023-05-18 | マジェンタ セラピューティクス インコーポレイテッド | T細胞二重特異性結合タンパク質 |
WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
WO2023111311A1 (en) | 2021-12-16 | 2023-06-22 | Universität Basel | Discernible cell surface protein variants of cd117 for use in cell therapy |
WO2024008910A1 (en) | 2022-07-07 | 2024-01-11 | Cimeio Therapeutics Ag | Antibodies targeting cd117 |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19600589C1 (de) * | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antikörper A3C6E2 |
WO1998025957A2 (en) | 1996-12-13 | 1998-06-18 | Human Genome Sciences, Inc. | HUMAN Prt1-LIKE SUBUNIT PROTEIN (hPrt1) AND HUMAN eIF4G-LIKE PROTEIN (p97) GENES |
US6372448B1 (en) | 1998-12-30 | 2002-04-16 | Millennium Pharmaceuticals, Inc. | Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US7329737B2 (en) | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
WO2007054816A2 (en) | 2005-11-14 | 2007-05-18 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之c-kit抗體 |
ATE521366T1 (de) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
PT3255061T (pt) | 2006-11-03 | 2021-07-26 | Univ Leland Stanford Junior | Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto |
CA2694396A1 (en) | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binding agents directed to kdr and uses thereof - 035 |
RU2546254C9 (ru) | 2008-11-07 | 2015-07-10 | Гэлэкси Биотех, Ллс. | Моноклональные антитела к рецептору 2 фактора роста фибробластов |
JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
HUE050296T2 (hu) | 2009-04-08 | 2020-11-30 | Faulstich Heinz Dr | Amatoxinnel fegyveres terápiás sejtfelszíni kötõ komponensek, amelyeket daganatterápiára terveztek |
CN102858799A (zh) | 2010-02-18 | 2013-01-02 | 明治制果药业株式会社 | 抗铜绿假单胞菌的i血清型脂多糖的抗体 |
KR101653030B1 (ko) | 2010-08-13 | 2016-08-31 | 로슈 글리카트 아게 | 항-테나신-c a2 항체 및 이의 사용 방법 |
EP2436398B1 (en) | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
US20120189612A1 (en) * | 2011-01-25 | 2012-07-26 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy |
EP3763740A1 (en) * | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
EP3019629A4 (en) | 2013-07-12 | 2017-01-18 | Biogen International Neuroscience GmbH | Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease |
WO2015057942A1 (en) | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides |
EP3065773A1 (en) * | 2013-11-05 | 2016-09-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human neutralizing anti-kit antibodies and uses thereof |
JP6606505B2 (ja) | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗SIRPα抗体および二重特異性マクロファージ増強抗体 |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
CA2978064A1 (en) * | 2015-03-09 | 2016-09-15 | Heidelberg Pharma Gmbh | Amatoxin-antibody conjugates |
US10889646B2 (en) | 2015-03-25 | 2021-01-12 | Children's Hospital Medical Center | Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation |
BR112017021536A2 (pt) | 2015-04-06 | 2018-07-03 | Harvard College | composições e métodos para o condicionamento não mieloablativo |
IL254887B2 (en) | 2015-04-07 | 2023-11-01 | Alector Llc | Anti-sortilin antibodies and methods of using them |
US10683506B2 (en) * | 2015-04-10 | 2020-06-16 | The Methodist Hospital System | CD117 ligand-drug conjugates for targeted cancer therapy |
MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
JP2019500893A (ja) | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Pd−1及びtim−3に特異的に結合する抗体及びそれらの使用 |
MA46419A (fr) | 2016-02-05 | 2018-12-12 | Genmab As | Molécule de liaison aux antigènes multispécifique présentant de meilleures caractéristiques d'internalisation |
EP3445401A4 (en) | 2016-04-20 | 2019-11-20 | Hangzhou DAC Biotech Co, Ltd | DERIVATIVES OF AMANITA TOXINES AND THEIR CONJUGATION TO A CELL BINDING MOLECULE |
US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
JP7062647B2 (ja) | 2016-06-17 | 2022-05-06 | マジェンタ セラピューティクス インコーポレイテッド | Cd117+細胞を枯渇させるための組成物及び方法 |
US20200188527A1 (en) | 2017-03-31 | 2020-06-18 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
WO2019084064A2 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
-
2018
- 2018-10-23 WO PCT/US2018/057180 patent/WO2019084064A2/en unknown
- 2018-10-23 US US16/168,823 patent/US10899843B2/en active Active
- 2018-10-23 JP JP2020523244A patent/JP7280254B2/ja active Active
- 2018-10-23 BR BR112020008228-7A patent/BR112020008228A2/pt unknown
- 2018-10-23 KR KR1020207014624A patent/KR20200069364A/ko unknown
- 2018-10-23 MX MX2020004140A patent/MX2020004140A/es unknown
- 2018-10-23 CN CN201880075607.2A patent/CN111372608B/zh active Active
- 2018-10-23 AU AU2018355244A patent/AU2018355244A1/en active Pending
- 2018-10-23 SG SG11202003280SA patent/SG11202003280SA/en unknown
- 2018-10-23 EP EP18870545.3A patent/EP3700568A4/en active Pending
- 2018-10-23 CA CA3079897A patent/CA3079897A1/en active Pending
-
2020
- 2020-04-21 CO CONC2020/0004906A patent/CO2020004906A2/es unknown
- 2020-04-22 IL IL274154A patent/IL274154A/en unknown
- 2020-11-24 US US17/103,866 patent/US11958908B2/en active Active
-
2023
- 2023-05-11 JP JP2023078719A patent/JP2023113666A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018355244A1 (en) | 2020-04-09 |
JP2023113666A (ja) | 2023-08-16 |
US10899843B2 (en) | 2021-01-26 |
CA3079897A1 (en) | 2019-05-02 |
JP7280254B2 (ja) | 2023-05-23 |
US20190153114A1 (en) | 2019-05-23 |
KR20200069364A (ko) | 2020-06-16 |
JP2021500375A (ja) | 2021-01-07 |
US20210206872A1 (en) | 2021-07-08 |
WO2019084064A4 (en) | 2019-08-08 |
CN111372608B (zh) | 2024-07-02 |
SG11202003280SA (en) | 2020-05-28 |
BR112020008228A2 (pt) | 2020-10-13 |
WO2019084064A3 (en) | 2019-06-20 |
EP3700568A4 (en) | 2021-11-10 |
CN111372608A (zh) | 2020-07-03 |
EP3700568A2 (en) | 2020-09-02 |
WO2019084064A2 (en) | 2019-05-02 |
CO2020004906A2 (es) | 2020-05-05 |
US11958908B2 (en) | 2024-04-16 |
IL274154A (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004140A (es) | Composiciones y metodos para la eliminacion de celulas cd117+. | |
MX2018015684A (es) | Composiciones y metodos para el agotamiento de celulas cd117. | |
WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
CO2021006259A2 (es) | Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos | |
MX2018015683A (es) | Composiciones y métodos para el agotamiento de células. | |
MX2021004579A (es) | Métodos para trasplante de células madre hematopoyéticas alogénicas. | |
BR112021021165A2 (pt) | Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos | |
CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
MX2020008244A (es) | Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella. | |
MX2022011546A (es) | Composiciones y metodos para el agotamiento de celulas cd137+. | |
EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
CO2020006865A2 (es) | Composiciones y métodos para el agotamiento de células cd5+ | |
AR115081A1 (es) | Aislados de microbacterias y sus usos | |
EA202191122A1 (ru) | СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ | |
CO2020007275A2 (es) | Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas | |
BR112022008371A2 (pt) | Anticorpos anti-cd45 e conjugados dos mesmos | |
WO2020219748A3 (en) | Anti-cd117 antibodies and uses thereof | |
MX2021005245A (es) | Composiciones de oligosacaridos y metodos de uso de las mismas. | |
WO2020219778A3 (en) | Anti-cd117 antibody-drug conjugates and uses thereof | |
AR123116A1 (es) | Composiciones y métodos para la disminución de células cd117⁺ | |
EA202192964A1 (ru) | Комбинированная терапия | |
AR120316A1 (es) | Aislados microbacterianos y sus usos | |
AR120352A1 (es) | Anticuerpos anti-cd45 y sus conjugados | |
EA202090689A1 (ru) | Композиции и способы истощения клеток cd117+ |